Hadziyannis SJ - Search Results

1

Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis.

Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Papatheodoridis GV, et al. Among authors: hadziyannis sj. Gut. 2003 Mar;52(3):404-9. doi: 10.1136/gut.52.3.404. Gut. 2003. PMID: 12584224 Free PMC article.

2

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.

Hadziyannis SJ, Papatheodoridis GV. Hadziyannis SJ, et al. Semin Liver Dis. 2006 May;26(2):130-41. doi: 10.1055/s-2006-939751. Semin Liver Dis. 2006. PMID: 16673291 Review.

3

Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B.

Cholongitas E, Papatheodoridis GV, Manesis EK, Petraki K, Tiniakos D, Hadziyannis SJ. Cholongitas E, et al. Among authors: hadziyannis sj. J Med Virol. 2011 Jul;83(7):1165-71. doi: 10.1002/jmv.21780. J Med Virol. 2011. PMID: 21567420

4

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.

Papatheodoridis GV, Manesis E, Hadziyannis SJ. Papatheodoridis GV, et al. Among authors: hadziyannis sj. J Hepatol. 2001 Feb;34(2):306-13. doi: 10.1016/s0168-8278(00)00094-5. J Hepatol. 2001. PMID: 11281561 Clinical Trial.

5

Diagnosis and management of pre-core mutant chronic hepatitis B.

Papatheodoridis GV, Hadziyannis SJ. Papatheodoridis GV, et al. Among authors: hadziyannis sj. J Viral Hepat. 2001 Sep;8(5):311-21. doi: 10.1046/j.1365-2893.2001.00303.x. J Viral Hepat. 2001. PMID: 11555188 Review.

6

Review article: current management of chronic hepatitis B.

Papatheodoridis GV, Hadziyannis SJ. Papatheodoridis GV, et al. Among authors: hadziyannis sj. Aliment Pharmacol Ther. 2004 Jan 1;19(1):25-37. doi: 10.1046/j.1365-2036.2003.01810.x. Aliment Pharmacol Ther. 2004. PMID: 14687164 Review.

7

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.

Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Papatheodoridis GV, et al. Among authors: hadziyannis sj. Hepatology. 2002 Jul;36(1):219-26. doi: 10.1053/jhep.2002.33894. Hepatology. 2002. PMID: 12085368

8

Treatment of HBeAg-negative chronic hepatitis B.

Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Hadziyannis SJ, et al. Semin Liver Dis. 2003 Feb;23(1):81-8. doi: 10.1055/s-2003-37584. Semin Liver Dis. 2003. PMID: 12616453 Review.

9

Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.

Hadziyannis SJ, Papatheodoridis GV. Hadziyannis SJ, et al. Expert Opin Pharmacother. 2003 Apr;4(4):541-51. doi: 10.1517/14656566.4.4.541. Expert Opin Pharmacother. 2003. PMID: 12667117 Review.

10

Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.

Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Manesis EK, et al. Among authors: hadziyannis sj. Am J Gastroenterol. 2003 Oct;98(10):2261-7. doi: 10.1111/j.1572-0241.2003.07715.x. Am J Gastroenterol. 2003. PMID: 14572577

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters